Clinical Core

临床核心

• 批准号: 10407979
• 负责人: DOUGLAS R GALASKO
• 金额: $ 114.83万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-05-01 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10407979
• 关键词: Address; Adopted; Age; Aging; Alzheimer' s Disease; Area; Autopsy; Biochemical; Biological Markers; Biopsy; Blood; Blood specimen; Brain; Brain Chemistry; Brain Pathology; Brain imaging; Cells; Cessation of life; Classification; Clinical; Clinical Research; Clinical Trials; Cognition; Cognitive; Cognitive aging; Consent; DNA; Data; Data Set; Data Store; Databases; Dementia; Diagnosis; Disease; Early Diagnosis; Elderly; Enrollment; Environment; Excision; Funding; Genetic; Heterogeneity; Hippocampus (Brain); Human Microbiome; Image; Latino; Latino Population; Lewy Body Disease; Link; Magnetic Resonance Imaging; Measures; Medical Genetics; Memory; Methodology; Mexican Americans; Neurodegenerative Disorders; Participant; Pathology; Persons; Phenotype; Physiological; Plasma; Pluripotent Stem Cells; Population; Positron-Emission Tomography; Quality Control; Registries; Research; Research Support; Sampling; Skin; Spinal Puncture; Staging; Structure; Symptoms; Temporal Lobe; Testing; United States National Institutes of Health; Variant; Work; aging brain; alpha synuclein; biomarker evaluation; brain magnetic resonance imaging; cell transformation; clinical phenotype; clinically significant; cognitive testing; cohort; data management; data sharing; dementia risk; follow-up; hazard; hippocampal sclerosis; imaging genetics; indexing; induced pluripotent stem cell; innovation; interest; meetings; member; metabolomics; mild cognitive impairment; minority subjects; neuropathology; novel; novel marker; outreach; pre-clinical; ranpirnase; recruit; response; social; symposium; tau Proteins; volunteer

CLINICAL CORE SUMMARY/ ABSTRACT The primary aim of the Clinical Core will be to enroll, characterize and follow a cohort maintained at 500-600 elders to support many types of research into Alzheimer’s Disease and Related Disorders. People who are enrolled will include some with normal cognition, some of whom may have markers of Alzheimer’s in their brain already, people with mild cognitive impairment and mild Alzheimer’s, and people with other types of neurodegenerative disorders, including Lewy Body Disease and Fronto-Temporal Lobar Degeneration. The core will enroll minority subjects as part of the groups that are followed, in particular Latinos. In addition to collecting and storing data about the ADRC participants at UCSD, the core will include components that are part of a national effort across centers, called the Uniform Data Set (UDS). The Core will submit UDS data on all subjects it follows to the national Alzheimer’s Coordinating Center (NACC). This will allow data sharing with a large national database. The Clinical Core will perform further testing beyond the tests required for the UDS. The core will draw a sample of blood for DNA, plasma and serum from participants, and will obtain CSF samples by lumbar puncture from those who agree. The core will obtain skin biopsies to be used to transform the cells in the skin into cells that can change into many identities (called pluripotent stem cells). Participants will have MRI brain imaging and PET imaging to support research into brain changes and pathology. Blood, CSF, skin biopsies and imaging will be stored at UCSD to allow for further analysis, and it may be available to share with collaborators. All participants will be invited to undergo follow-up research assessments once per year, to determine change in brain functioning, memory and other abilities. In subjects who consent, after their death the core will arrange for autopsy removal of the brain, for pathology analysis and to support further research. Some of the particular areas where the core will focus its efforts are in novel cognitive tests and assessing the brain through biomarkers related to structure, function, pathology and chemistry of the brain. This may help in early detection of change before major symptoms of dementia have arisen. Alzheimer’s disease has different features and progresses at varying rates, and we will try to identify factors that may account for this variation. Another area of interest for the core is in developing better ways to assess Latino participants, supported through social, cultural, and research expertise of the Latino Core. Finally, the core will work with other members of the ADRC to maintain and expand a Registry of research- ready volunteers.

临床核心摘要/摘要 临床核心的主要目的是注册，表征和遵循维持在500-600的队列 长辈支持许多类型的对阿尔茨海默氏病和相关疾病的研究。是的人 注册将包括一些具有正常认知的人，其中一些可能在大脑中有阿尔茨海默氏症的标记 患有轻度认知障碍和轻度阿尔茨海默氏症的人，还有其他类型的人 神经退行性疾病，包括Lewy身体疾病和额颞叶变性。这 核心将招募少数群体作为所遵循的群体的一部分，尤其是拉丁美洲人。 除了在UCSD收集和存储有关ADRC参与者的数据外，核心还将包括 是整个中心努力的一部分的组成部分，称为统一数据集（UDS）。核心意愿 向国家阿尔茨海默氏症协调中心（NACC）提交所有主题的UDS数据。这会 使用大型国家数据库允许数据共享。临床核心将进行进一步的测试 UDS所需的测试。 核心将从参与者那里抽取血液样本的DNA，等离子体和血清，并获得CSF 同意的人的腰椎刺穿样本。核心将获得用于转化的皮肤活检 皮肤中的细胞进入细胞，可以变成许多身份（称为多能干细胞）。参与者 将具有MRI脑成像和PET成像，以支持对大脑变化和病理学的研究。血， CSF，皮肤活检和成像将存储在UCSD中以进行进一步的分析，并且可以使用 与合作者分享。 所有参与者将被邀请每年接受一次后续研究评估，以确定 大脑功能，记忆和其他能力的变化。在同意的受试者中，核心将核心 安排去除大脑的尸检，以进行病理分析并支持进一步的研究。 核心将集中精力的某些特定领域是在新颖的认知测试中 大脑通过与大脑的结构，功能，病理和化学有关的生物标志物。这可能会有所帮助 在痴呆症重大症状之前的早期发现发生了变化。阿尔茨海默氏病不同 特征和以不同速度的进展，我们将尝试确定可能解释这种变化的因素。 核心的另一个感兴趣的领域是开发更好的方法来评估拉丁裔参与者，支持 通过拉丁裔核心的社会，文化和研究专业知识。 最后，核心将与ADRC的其他成员合作维护和扩展研究注册表 - 现成的志愿者。